The BioJobBlog reports that Merck and Sinopharm have reached an agreement for the distribution of Merck's cervical cancer vaccine - Gardasil in China. The move is Merck's first into a distribution partnership in China and is likely a harbinger of more activity here and in other developing markets worldwide.
China is projected to have high pharmaceutical growth rates in the next decade with the emergence of its middle class, and has high cervical cancer rates in particular. The HPV vaccine distribution agreement seems like a logical start for Merck and one of China's largest biopharm companies.
Posted by Bruce Lehr July 28th 2010.